Phosphorothioate-stimulated cellular uptake of siRNA: A cell culture model for mechanistic studies

Current Pharmaceutical Design

Volumn 14, Issue 34, 2008, Pages 3666-3673

  Detzer, A ^a   Overhoff, M ^a,c   Mescalchin, A ^a,b   Rompf, M ^a   Sczakiel, G ^a,b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b Kompetenzzentrum fuer Drug Design und Target Monitoring   (Germany)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Argonaute 2; Caveolae; ER; Golgi; Ilimaquinone; Intracellular trapping; RNAi; Sub cellular localisation

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ARGONAUTE 2 PROTEIN; CAVEOLIN; CELL PENETRATING PEPTIDE; LAMIN A; LAMIN C; LIPOFECTAMINE; LIPOFECTAMINE 2000; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID; PLASMID DNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; EIF2C2 PROTEIN, HUMAN; INITIATION FACTOR 2; OLIGONUCLEOTIDE PHOSPHOROTHIOATE;

CELL BASED GENE THERAPY; CELL CULTURE; CELL FRACTIONATION; CELL MEMBRANE TRANSPORT; CELL MIGRATION; CELL STIMULATION; CELLULAR DISTRIBUTION; DRUG PENETRATION; DRUG UPTAKE; ENDOPLASMIC RETICULUM; FLUORESCENCE MICROSCOPY; GENE ACTIVITY; GENE LOCATION; GENE SILENCING; GENETIC TRANSFECTION; GOLGI COMPLEX; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; RNA INTERFERENCE; BIOLOGICAL MODEL; CENTRIFUGATION; CULTURE TECHNIQUE; METABOLISM;

CELL CULTURE TECHNIQUES; CENTRIFUGATION; ENDOPLASMIC RETICULUM; EUKARYOTIC INITIATION FACTOR-2; GOLGI APPARATUS; HUMANS; MICROSCOPY, FLUORESCENCE; MODELS, BIOLOGICAL; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; RNA, SMALL INTERFERING; SUBCELLULAR FRACTIONS;

EID: 59849125915     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786898770     Document Type: Review

References (69)

1. Juliano R, Alam MR, Dixit V, Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008; 36: 4158-71.
2. Lian S, Fritzler MJ, Katz J, Hamazaki T, Terada N, Satoh M, et al. Small interfering RNA-mediated silencing induces targetdependent assembly of GW/P bodies. Mol Biol Cell 2007; 18: 3375-87.
3. Mescalchin A, Detzer A, Wecke M, Overhoff M, Wunsche W, Sczakiel G. Cellular uptake and intracellular release are major obstacles to the therapeutic application of siRNA: Novel options by phosphorothioate-stimulated delivery. Expert Opin Biol Ther 2007; 7: 1531-8.
4. Rüdel S, Flatley A, Weinmann L, Kremmer E, Meister G. A multifunctional human Argonaute2-specific monoclonal antibody. RNA 2008; 14: 1244-53.
5. Mayor S, Pagano RE. Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 2007; 8: 603-12.
6. Ungewickell EJ, Hinrichsen L. Endocytosis: Clathrin-mediated membrane budding. Curr Opin Cell Biol 2007; 19: 417-25.
7. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 2003; 422: 37-44.
8. Kirkham M, Parton RG. Clathrin-independent endocytosis: New insights into caveolae and non-caveolar lipid raft carriers. Biochim Biophys Acta 2005; 1745: 273-86.
9. Benmerah A, Lamaze C. Clathrin-coated pits: Vive la difference? Traffic 2007; 8: 970-82.
10. Cavalli V, Corti M, Gruenberg J. Endocytosis and signaling cascades: A close encounter. FEBS Lett 2001; 498: 190-6.
11. van der Goot FG, Gruenberg J. Intra-endosomal membrane traffic. Trends Cell Biol 2006; 16: 514-21.
12. Medina-Kauwe LK. "Alternative"endocytic mechanisms exploited by pathogens: New avenues for therapeutic delivery? Adv Drug Deliv Rev 2007; 59: 798-809.
13. Nomura R, Kiyota A, Suzaki E, Kataoka K, Ohe Y, Miyamoto K, et al. Human coronavirus 229E binds to CD13 in rafts and enters the cell through caveolae. J Virol 2004; 78: 8701-8.
14. Nunes-Correia I, Eulalio A, Nir S, Pedroso de Lima MC. Caveolae as an additional route for influenza virus endocytosis in MDCK cells. Cell Mol Biol Lett 2004; 9: 47-60.
15. Pietiainen V, Marjomaki V, Upla P, Pelkmans L, Helenius A, Hyypia T. Echovirus 1 endocytosis into caveosomes requires lipid rafts, dynamin II, and signaling events. Mol Biol Cell 2004; 15: 4911-25.
16. Richterova Z, Liebl D, Horak M, Palkova Z, Stokrova J, Hozak P, et al. Caveolae are involved in the trafficking of mouse polyomavirus virions and artificial VP1 pseudocapsids toward cell nuclei. J Virol 2001; 75: 10880-91.
17. Westermann M, Leutbecher H, Meyer HW. Membrane structure of caveolae and isolated caveolin-rich vesicles. Histochem Cell Biol 1999; 111: 71-81
18. Anderson RG. The caveolae membrane system. Annu Rev Biochem 1998; 67: 199-225.
19. Nichols B. Caveosomes and endocytosis of lipid rafts. J Cell Sci 2003; 116: 4707-14.
20. Pelkmans L, Helenius A. Endocytosis via caveolae. Traffic 2002; 3: 311-20.
21. Parton RG. Caveolae meet endosomes: A stable relationship? Dev Cell 2004; 7: 458-60.
22. Pelkmans L, Kartenbeck J, Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol 2001; 3: 473-83.
23. Norkin LC, Kuksin D. The caveolae-mediated SV40 entry pathway bypasses the Golgi complex en route to the endoplasmic reticulum. Virol J 2005; 2: 38.
24. Oh P, Borgstrom P, Witkiewicz H, Li Y, Borgstrom BJ, Chrastina A, et al. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol 2007; 25: 327-37.
25. Abes R, Arzumanov AA, Moulton HM, Abes S, Ivanova GD, Iversen PL, et al. Cell-penetrating-peptide-based delivery of oligonucleotides: An overview. Biochem Soc Trans 2007; 35: 775-9.
26. Dietz GP, Bahr M. Delivery of bioactive molecules into the cell: The Trojan horse approach. Mol Cell Neurosci 2004; 27: 85-131.
27. Lebleu B, Moulton HM, Abes R, Ivanova GD, Abes S, Stein DA, et al. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev 2008; 60: 517-29.
28. Veldhoen S, Laufer SD, Trampe A, Restle T. Cellular delivery of small interfering RNA by a non-covalently attached cellpenetrating peptide: quantitative analysis of uptake and biological effect. Nucleic Acids Res 2006; 34: 6561-73.
29. Peer D, Zhu P, Carman CV, Lieberman J, Shimaoka M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci USA 2007; 104: 4095-100.
30. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005; 23: 709-17.
31. Vornlocher HP. Antibody-directed cell-type-specific delivery of siRNA. Trends Mol Med 2006; 12: 1-3.
32. Minakuchi Y, Takeshita F, Kosaka N, Sasaki H, Yamamoto Y, Kouno M, et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 2004; 32: E109.
33. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004; 64: 3365-70.
34. Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, Hirai K, et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005; 102: 12177-82.
35. Cheng K, Ye Z, Guntaka RV, Mahato RI. Enhanced hepatic uptake and bioactivity of type alpha1(I) collagen gene promoter-specific triplex-forming oligonucleotides after conjugation with cholesterol. J Pharmacol Exp Ther 2006; 317: 797-805.
36. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432: 173-8.
37. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441: 111-4.
38. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario- DiCaprio K, et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 2006; 193: 1650-7.
39. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23: 1002-7.
40. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 2006; 13: 1222-34.
41. Overhoff M, Sczakiel G. Phosphorothioate-stimulated uptake of short interfering RNA by human cells. EMBO Rep 2005; 6: 1176-81.
42. Detzer A. Studies on the intracellular site of action of siRNA. Master thesis, 2007, University of Luebeck.
43. Tagawa A, Mezzacasa A, Hayer A, Longatti A, Pelkmans L, Helenius A. Assembly and trafficking of caveolar domains in the cell: Caveolae as stable, cargo-triggered, vesicular transporters. J Cell Biol 2005; 170: 769-79.
44. Rompf M. Studies on the Relationship Between Subcellular Localization and Biological Efficiency of siRNA and siRNA-Peptide Conjugates. Master thesis, 2007, University of Luebeck.
45. Laufer SD, Restle T. Peptide-mediated cellular delivery of oligonucleotide- based therapeutics in vitro: Quantitative evaluation of overall efficacy employing easy to handle reporter systems. Curr Pharm Des ??????
46. Veldhoen S, Laufer SD, Restle T. Recent Developments in Peptidebased Nucleic Acid Delivery. Int J Mol Sci 2008; 9: 1276-320.
47. Overhoff M. Untersuchungen zur Struktur-Funktions-Beziehung von small interfering RNA (siRNA) und ein neuartiges Konzept zu ihrer Einschleusung in Saugerzellen. PhD thesis: University of Luebeck; 2006.
48. Overhoff M, Wunsche W, Sczakiel G. Quantitative detection of siRNA and single-stranded oligonucleotides: Relationship between uptake and biological activity of siRNA. Nucleic Acids Res 2004; 32: E170.
49. Takizawa PA, Yucel JK, Veit B, Faulkner DJ, Deerinck T, Soto G, et al. Complete vesiculation of Golgi membranes and inhibition of protein transport by a novel sea sponge metabolite, ilimaquinone. Cell 1993; 73: 1079-90.
50. Wang HJ, Benlimame N, Nabi I. The AMF-R tubule is a smooth ilimaquinone-sensitive subdomain of the endoplasmic reticulum. J Cell Sci 1997; 110: 3043-53.
51. Le PU, Guay G, Altschuler Y, Nabi IR. Caveolin-1 is a negative regulator of caveolae-mediated endocytosis to the endoplasmic reticulum. J Biol Chem 2002; 277: 3371-9.
52. Le PU, Nabi IR. Distinct caveolae-mediated endocytic pathways target the Golgi apparatus and the endoplasmic reticulum. J Cell Sci 2003; 116: 1059-71.
53. Billy E, Brondani V, Zhang H, Muller U, Filipowicz W. Specific interference with gene expression induced by long, double-stranded RNA in mouse embryonal teratocarcinoma cell lines. Proc Natl Acad Sci USA 2001; 98: 14428-33.
54. Chiu YL, Ali A, Chu CY, Cao H, Rana TM. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 2004; 11: 1165-75.
55. Lavigne C, Thierry AR. Specific subcellular localization of siRNAs delivered by lipoplex in MCF-7 breast cancer cells. Biochimie 2007; 89: 1245-51.
56. van der Aa MA, Huth US, Hafele SY, Schubert R, Oosting RS, Mastrobattista E, et al. Cellular uptake of cationic polymer-DNA complexes via caveolae plays a pivotal role in gene transfection in COS-7 cells. Pharm Res 2007; 24: 1590-8.
57. Rockwell P, O'Connor WJ, King K, Goldstein NI, Zhang LM, Stein CA. Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci USA 1997; 94: 6523-8.
58. Szabo A, Laki J, Madsen HO, Dosa E, Prohaszka Z, Rugonfalvi- Kiss S, et al. Early rise in serum VEGF and PDGF levels predisposes patients with a normal MBL2 genotype to restenosis after eversion endarterectomy. Stroke 2007; 38: 2247-53.
59. Liu P, Ying Y, Ko YG, Anderson RG. Localization of platelet-derived growth factor-stimulated phosphorylation cascade to caveolae. J Biol Chem 1996; 271: 10299-303.
60. Sargiacomo M, Sudol M, Tang Z, Lisanti MP. Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J Cell Biol 1993; 122: 789-807.
61. Shenoy-Scaria AM, Dietzen DJ, Kwong J, Link DC, Lublin DM. Cysteine3 of Src family protein tyrosine kinase determines palmitoylation and localization in caveolae. J Cell Biol 1994; 126: 353-63.
62. Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev 2004; 15: 237-54.
63. Levin AA. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999; 1489: 69-84.
64. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003; 270: 1628-44.
65. Eckstein F. Phosphorothioation of DNA in bacteria. Nat Chem Biol 2007; 3: 689-90.
66. Wang L, Chen S, Xu T, Taghizadeh K, Wishnok JS, Zhou X, et al. Phosphorothioation of DNA in bacteria by dnd genes. Nat Chem Biol 2007; 3: 709-10.
67. Eckstein F, Gindl H. Polyribonucleotides containing a phosphorothioate backbone. Eur J Biochem 1970; 13: 558-64.
68. Eckstein F. Nucleoside phosphorothioates. Annu Rev Biochem 1985; 54: 367-402.
69. Verma S, Eckstein F. Modified oligonucleotides: Synthesis and strategy for users. Annu Rev Biochem 1998; 67: 99-134.